Key statistics
On Monday, Akero Therapeutics Inc (0K4:STU) closed at 46.57, -10.99% below its 52-week high of 52.32, set on Feb 10, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 46.57 |
|---|---|
| High | 46.57 |
| Low | 46.57 |
| Bid | 46.88 |
| Offer | 47.06 |
| Previous close | 46.57 |
| Average volume | -- |
|---|---|
| Shares outstanding | -- |
| Free float | -- |
| P/E (TTM) | -- |
| Market cap | -- |
| EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Dec 08 2025.
More ▼
Announcements
- Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025
- Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion
- Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025
- Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
- Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH
- Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
- Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
- Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
- Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
- Akero Therapeutics et HistoIndex présentent de nouvelles analyses de l’essai de phase IIb HARMONY lors de présentations orales et d’affiches lors du congrès 2025 de l’EASL
More ▼
